AI Article Synopsis
- Immune evasion plays a crucial role in the development and progression of pancreatic ductal adenocarcinoma (PDAC), and the specific mechanisms are not completely understood.
- Tumor-derived progranulin (PGRN) is linked to poorer patient survival and is associated with low expression of MHC class I molecules and reduced CD8 T cell presence in PDAC tumors.
- Blocking PGRN in mouse models slows down tumor growth and enhances the immune response against tumors expressing specific antigens, highlighting the significant role of PGRN in immune regulation in PDAC.
Article Abstract
Immune evasion is indispensable for cancer initiation and progression, although its underlying mechanisms in pancreatic ductal adenocarcinoma (PDAC) are not fully known. Here, we characterize the function of tumor-derived PGRN in promoting immune evasion in primary PDAC. Tumor- but not macrophage-derived PGRN is associated with poor overall survival in PDAC. Multiplex immunohistochemistry shows low MHC class I (MHCI) expression and lack of CD8 T cell infiltration in PGRN-high tumors. Inhibition of PGRN abrogates autophagy-dependent MHCI degradation and restores MHCI expression on PDAC cells. Antibody-based blockade of PGRN in a PDAC mouse model remarkably decelerates tumor initiation and progression. Notably, tumors expressing LCMV-gp33 as a model antigen are sensitized to gp33-TCR transgenic T cell-mediated cytotoxicity upon PGRN blockade. Overall, our study shows a crucial function of tumor-derived PGRN in regulating immunogenicity of primary PDAC.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8748938 | PMC |
| http://dx.doi.org/10.1038/s41467-021-27088-9 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!